Sector News

Novartis to move UK headquarters to London

November 30, 2018
Life sciences

Novartis is moving its UK headquarters to London, in a multi-million pound investment in UK life sciences, which will be complete by January 2020.

The Swiss drugs giant said it is relocating its UK headquarters to The WestWorks building on the White City Place campus, in a bold move to join London’s latest emerging life sciences cluster.

The WestWorks is home to a number of technology and innovation companies.

The area is emerging to be London’s latest life sciences cluster and is quickly becoming home to a number of pioneering life sciences companies, as well as Imperial College London’s major new research and innovation campus.

“The nature of healthcare and medicine is changing and as we pivot towards becoming a focused medicines company, powered by digital and data, we want to be closer to our customers and partners, and become better networked in the healthcare and life science ecosystem,” said Haseeb Ahmad, Novartis UK country president.

He continued, “White City is quickly becoming one of the UK’s life sciences and technology districts, and the ethos of The WestWorks campus complements how we work to deliver on our strategy to reimagine medicine.”

Professor David Gann, VP of innovation at Imperial College also commented on the move, stating: “Novartis is a natural fit for White City’s booming life sciences ecosystem, and we hope that this move will pave the way to new collaborations and partnerships to enhance our work in this area.”

By Anna Smith

Source: Pharma Times

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach